Izonsteride
Alternative Names: LY 320236Latest Information Update: 09 Oct 2007
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; University of Chicago Cancer Research Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer